Cost Recovery The Company has submitted an application to the U.S. Food and Drug Administration (“FDA”) for cost recovery for its Phase II pivotal trial in brain cancer. If this application is granted, the Company will be permitted to charge patients or their insurers for the direct manufacturing costs of DCVax®-Brain during this clinical trial. Cost recovery is an extraordinary measure, and is only allowed in rare cases involving certain kinds of special circumstances. The Company considers its cost recovery application to FDA extremely important and central to the timing and overall implementation of its product development programs. The Company expects to receive a decision from the FDA on its cost recovery application in the near future.